The inhalation industry has been discussing the green transition for the best part of a decade, and the approval of the first low carbon pressurised Metered Dose Inhaler (pMDI) in 2025 marked an important milestone.
However, significant challenges still stand between first approval and full industry transition.
In our recent roundtable, featured in International Pharmaceutical Industry, Bespak® experts—Adam Kite, Ross Errington, Nick Atkinson, Tony Mallett and Benedicta Bakpa—examine the obstacles facing the industry, including limited manufacturing capacity, evolving regulatory requirements, formulation complexity and component compatibility.
The discussion also explores the practical solutions helping to support the next phase of the transition, from investment in specialist manufacturing infrastructure to the use of innovative simulation tools to accelerate development.
Drawing on expertise across commercial, technical, engineering and sustainability disciplines, the panel highlights how Bespak, the specialist inhalation contract development and manufacturing organisation (CDMO), is helping customers prepare for the next era of pMDIs.
Read the full article here.
